vs
Side-by-side financial comparison of SCYNEXIS INC (SCYX) and SPRUCE POWER HOLDING CORP (SPRU). Click either name above to swap in a different company.
SPRUCE POWER HOLDING CORP is the larger business by last-quarter revenue ($24.0M vs $18.6M, roughly 1.3× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs -28.6%, a 94.3% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 20.4%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 14.6%).
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
Spruce Finance is an American consumer finance company specializing in the residential solar finance and efficiency home improvement sectors in the U.S.
SCYX vs SPRU — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $24.0M |
| Net Profit | $12.3M | $-6.9M |
| Gross Margin | — | — |
| Operating Margin | 56.3% | 9.4% |
| Net Margin | 65.7% | -28.6% |
| Revenue YoY | 1808.5% | 20.4% |
| Net Profit YoY | 376.5% | -15.8% |
| EPS (diluted) | $0.25 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $24.0M | ||
| Q3 25 | $334.0K | $30.7M | ||
| Q2 25 | $1.4M | $33.2M | ||
| Q1 25 | $257.0K | $23.8M | ||
| Q4 24 | $977.0K | $20.0M | ||
| Q3 24 | $660.0K | $21.4M | ||
| Q2 24 | $736.0K | $22.5M | ||
| Q1 24 | $1.4M | $18.3M |
| Q4 25 | $12.3M | $-6.9M | ||
| Q3 25 | $-8.6M | $-860.0K | ||
| Q2 25 | $-6.9M | $-3.0M | ||
| Q1 25 | $-5.4M | $-15.3M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | $-2.8M | $-53.5M | ||
| Q2 24 | $-14.5M | $-8.6M | ||
| Q1 24 | $411.0K | $-2.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.8% | ||
| Q2 24 | — | 54.9% | ||
| Q1 24 | — | 51.5% |
| Q4 25 | 56.3% | 9.4% | ||
| Q3 25 | -2516.5% | 27.6% | ||
| Q2 25 | -701.0% | 26.8% | ||
| Q1 25 | -3350.2% | -7.1% | ||
| Q4 24 | — | -31.4% | ||
| Q3 24 | -1563.6% | -173.8% | ||
| Q2 24 | -1255.0% | -14.9% | ||
| Q1 24 | -692.5% | -19.7% |
| Q4 25 | 65.7% | -28.6% | ||
| Q3 25 | -2572.2% | -2.8% | ||
| Q2 25 | -504.8% | -8.9% | ||
| Q1 25 | -2097.7% | -64.4% | ||
| Q4 24 | — | -29.7% | ||
| Q3 24 | -425.5% | -250.4% | ||
| Q2 24 | -1964.4% | -38.2% | ||
| Q1 24 | 29.9% | -13.4% |
| Q4 25 | $0.25 | $-0.38 | ||
| Q3 25 | $-0.17 | $-0.05 | ||
| Q2 25 | $-0.14 | $-0.17 | ||
| Q1 25 | $-0.11 | $-0.84 | ||
| Q4 24 | — | $-0.36 | ||
| Q3 24 | $-0.06 | $-2.88 | ||
| Q2 24 | $-0.30 | $-0.45 | ||
| Q1 24 | $0.01 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $40.0M | $54.8M |
| Total DebtLower is stronger | — | $695.5M |
| Stockholders' EquityBook value | $49.4M | $121.3M |
| Total Assets | $59.0M | $837.3M |
| Debt / EquityLower = less leverage | — | 5.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $40.0M | $54.8M | ||
| Q3 25 | $37.9M | $53.6M | ||
| Q2 25 | $44.8M | $53.5M | ||
| Q1 25 | $40.6M | $61.9M | ||
| Q4 24 | $59.3M | $72.8M | ||
| Q3 24 | $68.8M | $113.7M | ||
| Q2 24 | $73.0M | $116.6M | ||
| Q1 24 | $80.2M | $120.6M |
| Q4 25 | — | $695.5M | ||
| Q3 25 | — | $705.6M | ||
| Q2 25 | — | $717.1M | ||
| Q1 25 | — | $723.8M | ||
| Q4 24 | — | $730.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $49.4M | $121.3M | ||
| Q3 25 | $36.4M | $124.9M | ||
| Q2 25 | $44.5M | $125.0M | ||
| Q1 25 | $50.5M | $130.8M | ||
| Q4 24 | $55.1M | $143.7M | ||
| Q3 24 | $58.5M | $151.6M | ||
| Q2 24 | $60.4M | $204.6M | ||
| Q1 24 | $74.1M | $213.0M |
| Q4 25 | $59.0M | $837.3M | ||
| Q3 25 | $51.1M | $857.1M | ||
| Q2 25 | $60.7M | $862.6M | ||
| Q1 25 | $67.9M | $878.0M | ||
| Q4 24 | $90.6M | $898.5M | ||
| Q3 24 | $99.0M | $806.8M | ||
| Q2 24 | $107.8M | $858.4M | ||
| Q1 24 | $118.3M | $867.9M |
| Q4 25 | — | 5.74× | ||
| Q3 25 | — | 5.65× | ||
| Q2 25 | — | 5.74× | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | 5.08× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.4M | $-3.3M |
| Free Cash FlowOCF − Capex | — | $-3.3M |
| FCF MarginFCF / Revenue | — | -13.7% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 1.50× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-3.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $-3.3M | ||
| Q3 25 | $-8.7M | $11.2M | ||
| Q2 25 | $-7.5M | $-2.3M | ||
| Q1 25 | $-7.5M | $-9.1M | ||
| Q4 24 | $-24.0M | $-13.5M | ||
| Q3 24 | $765.0K | $-1.1M | ||
| Q2 24 | $-10.9M | $-5.1M | ||
| Q1 24 | $-4.0M | $-22.2M |
| Q4 25 | — | $-3.3M | ||
| Q3 25 | — | $11.2M | ||
| Q2 25 | — | $-2.4M | ||
| Q1 25 | — | $-9.2M | ||
| Q4 24 | — | $-13.6M | ||
| Q3 24 | — | $-1.1M | ||
| Q2 24 | — | $-5.2M | ||
| Q1 24 | — | $-22.3M |
| Q4 25 | — | -13.7% | ||
| Q3 25 | — | 36.5% | ||
| Q2 25 | — | -7.3% | ||
| Q1 25 | — | -38.7% | ||
| Q4 24 | — | -68.3% | ||
| Q3 24 | — | -5.1% | ||
| Q2 24 | — | -23.1% | ||
| Q1 24 | — | -121.7% |
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | 1.50× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -9.75× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
SPRU
Segment breakdown not available.
